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Abstract
The multidrug resistance P-glycoprotein is an ATP-dependent drug pump that extrudes a broad range of hydrophobic
compounds out of cells. Its physiological role is likely to protect us from exogenous and endogenous toxins. The protein is
important because it contributes to the phenomenon of multidrug resistance during AIDS and cancer chemotherapy. We
have used cysteine-scanning mutagenesis and thiol-modification techniques to map the topology of the protein, show that
both nucleotide-binding domains are essential for activity, examine packing of the transmembrane segments, map the drug-
binding site, and show that there is cross-talk between the ATP-binding sites and the transmembrane segments. ß 1999
Elsevier Science B.V. All rights reserved.
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1. Introduction
P-glycoprotein (P-gp) was discovered by Juliano
and Ling [1]. It was overexpressed in cell lines that
were initially selected for resistance to a particular
cytotoxic agent. These cell lines were subsequently
shown to be resistant to many other cytotoxic agents
that had diverse chemical structures and intracellular
targets (multidrug resistance). It is generally accepted
that P-gp confers multidrug resistance by acting as
an ATP-dependent drug pump at the cell surface to
remove hydrophobic compounds out of the lipid bi-
layer (Fig. 1) (see comprehensive reviews in [2^4]).
Expression of P-gp in various mammalian tissues
is quite variable [5^11]. The relatively high levels of
P-gp expression in the epithelial cells of the intestine,
blood-brain barrier, blood-testis barrier, and adrenal
glands suggests that P-gp plays a very important role
in protecting the organism from the onslaught of
numerous toxins in our diet and environment [12].
The exact physiological role of P-gp, however, is not
known.
Studies on P-gp ‘knock-out’ mice show that the
protein is not essential. The mice remain fertile and
do not display any obvious phenotypic abnormal-
ities. They are, however, hypersensitive to accumula-
tion of cytotoxic drugs, and this is most acute in the
brain [13,14].
Chemotherapy is a major form of treatment for
many cancers. In tumors that do not express endog-
enous P-gp, there is initial success with remission of
the tumor during chemotherapy. Unfortunately, the
tumors recur in many cases because of induction of
P-gp expression following chemotherapy. In these
cases, the prognosis is poor. Tumors that express
endogenous P-gp usually complicate the chemother-
apy regimen. In these instances, the chemotherapy
regimen usually involves polypharmacy, and use of
drugs that have di¡erent chemical structures as well
as di¡erent intracellular targets (e.g., Vinca alkaloids,
epipodophyllotoxins, taxanes and actinomycin D).
Combination chemotherapy is used not only to at-
tack di¡erent aspects of the tumor cell cycle, but it
also coincidentally inhibits P-gp. An example is the
inclusion of cyclosporin A in the chemotherapy regi-
men for treating retinoblastoma [2]. Treatment of
retinoblastomas with vincristine alone is usually not
successful because a high percentage of these tumors
overexpress P-gp. Addition of a relatively high dose
of cyclosporin A during vincristine administration,
however, results in remission of the tumor. The com-
bination therapy works because P-gp has a relatively
higher a⁄nity for cyclosporin A. Therefore, cyclo-
sporin A likely acts as a competitive inhibitor [15].
P-gp has also been implicated in the poor thera-
peutic response of AIDS patients to protease inhib-
itors. Protease inhibitors such as indinavir, nel¢navir
and saquinavir are substrates of P-gp [16,17]. The
relatively high levels of expression of P-gp in the
gastrointestinal tract would account for the poor
oral absorption of these drugs. The problem is com-
pounded when P-gp in the blood-brain barrier pre-
vents penetration of these drugs into the central
nervous system.
Although combination chemotherapy to circum-
Fig. 1. Expression of P-gp confers multidrug resistance. Cyto-
toxic compounds enter the cell by di¡using through the lipid bi-
layer before binding to their intracellular target. Cells overex-
pressing P-gp (right) extract the cytotoxic compound from the
lipid bilayer and use the energy from ATP hydrolysis to extrude
them from the cell. These cells are viable even with the contin-
ued presence of the toxic compounds. The cells that do not ex-
press P-gp (left) accumulate these compounds and die very
shortly.
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vent the action of P-gp can result in the remission of
some tumors, it is not without disadvantages. The
use of several drugs during treatment also results in
increased side e¡ects for the patient, and this is often
an important limiting factor during therapy (i.e. a
balance between killing the tumor and ‘killing’ the
patient). In order to develop a second generation of
inhibitors that are speci¢c for P-gp, it is important to
know about its biosynthesis, structure and mecha-
nism. A particularly useful method for understanding
the structure and mechanism of P-gp is to use cys-
teine-scanning mutagenesis and thiol-modi¢cation
techniques. In this review, we summarize some of
the results from using a functional cysteine-less
(Cys-less) P-gp for biochemical analysis.
2. Construction of a functional Cys-less P-gp
P-gp is a typical ABC (ATP-binding cassette)
transporter [18]. The 1280 amino acids of human
P-gp are arranged in four domains: two transmem-
brane domains (TMDs) with six predicted transmem-
brane (TM) segments each and two nucleotide-bind-
ing domains (NBDs) [19^22]. The molecule is
tandemly duplicated with the two halves showing
about 43% amino acid identity. The protein contains
seven endogenous cysteine residues at positions 137,
431, 717, 956, 1074, 1125 and 1227 (Fig. 2). All of
the cysteines were mutated to alanine [23] resulting in
a Cys-less P-gp. Alanine is a relatively small neutral
amino acid that should cause minimal structural per-
turbations.
Initially, it seemed that serine would be a better
substitution than alanine because it is structurally
similar to alanine. We found, however, that substitu-
tion of cysteine with serine in the Walker A consen-
sus sites (residues 431 or 1074) caused structural dis-
ruption of P-gp (Loo and Clarke, unpublished). P-gp
mutants C431S or C1074S failed to mature to the cell
surface and were rapidly degraded.
Two modi¢cations were made to the Cys-less P-gp.
The ¢rst modi¢cation was to add the epitope for
monoclonal antibody A52 (derived from SERCA1
Ca2-ATPase [24]) to the COOH-terminal end of
the protein. This allowed us to follow expression of
Cys-less P-gp. The modi¢cation did not alter expres-
sion or activity [25]. SERCA1 is not normally ex-
pressed in the mammalian cell lines used for expres-
sion of the P-gp mutants. Therefore, the monoclonal
antibody A52 used in immunoblots results in very
low background. The A52 antibody tag is also useful
for quantitating the amount of P-gp-A52 expressed
using an ELISA with the puri¢ed SERCA1 as a
standard. The SERCA1 Ca2-ATPase is readily pu-
ri¢ed from rabbit muscle.
Instead of the A52 tag, 10 histidine residues were
added at the COOH-end of P-gp [26]. Histidine-
tagged P-gp mutants can be expressed, puri¢ed by
nickel-chelate chromatography and assayed for activ-
ity in 3^4 days. The fortuitous availability of nickel-
NTA spin columns (Qiagen, Inc.) made it relatively
easy to do 12^24 puri¢cations at one time. We have
constructed histidine-tagged P-gps containing either
six or 10 histidines at the COOH-end. Although both
types of P-gp can be recovered by nickel-chelate
chromatography, using P-gp with a (His)10 tag re-
sults in purer enzyme. This is because higher concen-
trations of imidazole (80 mM versus 20 mM for
(His)10 and (His)6, respectively) can be used during
Fig. 2. Construction of Cys-less P-glycoprotein. Wild-type P-gp
contains seven cysteine residues that were mutated to alanine
resulting in the Cys-less P-gp. A tag was added to the COOH-
end to facilitate detection by immunoblot analysis (epitope for
monoclonal antibody A52) or for puri¢cation (a 10-histidine)
by nickel-chelate chromatography. The numbered rectangles
represent the TM segments, and the horizontal rectangles repre-
sent the ‘Walker A’ consensus ATP-binding sites.
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the column washes to remove more impurities with
P-gp-( His)10. Large-scale expression and puri¢cation
of histidine-tagged P-gp can be achieved with bacu-
lovirus vectors and Sf9 insect cells (Loo and Clarke,
unpublished; [27]). The disadvantage with the insect
cell system is that it is tedious and time consuming
(takes weeks to months).
Although expression of Cys-less P-gp in insect cells
does not appear to be a problem [28], the same can-
not be said for expression in mammalian cells. An
initial problem with expression of the Cys-less P-gp
in mammalian cells was that biosynthesis was ine⁄-
cient relative to the wild-type enzyme. Introduction
of other cysteine residues at di¡erent places in the
Cys-less P-gp further inhibited maturation of the
protein. This appears to be a common problem
when generating a functional Cys-less protein. For
example, replacement of individual cysteine residues
is well tolerated by the PMA1 H-ATPase, but mul-
tiple replacements adversely a¡ected the structure of
the transporter such that it was unstable and did not
retain much activity [29].
A method to ‘boost’ expression of mature Cys-less
P-gp in mammalian cells was discovered during work
on processing mutants of P-gp. During structure-
function studies, we found that about 12% of the
point mutations in P-gp a¡ected processing of the
protein [25,30,31]. These mutations are found in the
TM segments, the intracellular or extracellular loops,
the linker region and in either nucleotide-binding
domain. The major product in P-gp-processing mu-
tants expressed in HEK 293 cells is a protein of
150 kDa, while that in wild-type P-gp is a protein
of 170 kDa. The processing mutants are retained in
the endoplasmic reticulum as core-glycosylated bio-
synthetic intermediates in association with chaper-
ones such as calnexin and Hsc70 and are rapidly
degraded [32,33]. The presence of these point muta-
tions must cause P-gp to adopt an unfavorable con-
formation that is recognized by the cell’s quality con-
trol mechanism. It was a pleasant surprise to
discover that the presence of drug substrates during
biosynthesis of these processing mutants ‘rescued’ all
of these processing mutants such that the major
product was now a protein of 170 kDa. These res-
cued mutant proteins are transported to the plasma
membrane in a functional form and are as stable as
the wild-type protein [34]. These results suggested
that the drug/substrate-binding site(s) must exist
transiently in the misprocessed mutants during bio-
synthesis (as in the wild-type enzyme), and that the
folding pathway for P-gp must involve numerous
transitional conformational states that are in equilib-
rium. The presence of drug/substrate at a critical
point must stabilize a particular structural conforma-
tion of the misprocessed mutants long enough to
allow proper folding and subsequent tra⁄cking to
the cell surface. If the drug/substrate is not present
to act as a ‘sca¡old’ at a critical point, then these
transient structures can proceed to a malfolded state,
and are subsequently degraded (degradation path-
way). Preliminary evidence suggests that this may
indeed be the case. As P-gp travels through the fold-
ing pathway, its structure changes from a trypsin-
Fig. 3. Schematic representation of rescue of processing mutants by drug substrates. (A) Wild-type P-gp is synthesized in the endo-
plasmic reticulum (ER) as a core-glycosylated protein that is then processed in the Golgi apparatus and subsequently tra⁄cked to the
plasma membrane. (B) P-gp processing mutants are retained in the ER as core-glycosylated intermediates and are rapidly degraded.
(C) The hydrophobic drug substrates di¡use to the ER, where they stabilize the processing mutant so that it adopts a ‘near-native’
structure and leaves the ER for processing (in the Golgi) and transport to the plasma membrane.
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sensitive conformation to a relatively trypsin-resist-
ant one [35]. This ‘drug rescue’ of the processing
mutants is schematically represented in Fig. 3.
Cysteine-scanning mutagenesis and thiol chemistry
were then used to answer the following questions:
Are both nucleotide-binding domains essential for
activity and are they equivalent?
How is the protein folded in the membrane?
Where are the drug-binding site(s)?
How is ATP hydrolysis coupled to drug trans-
port?
How does drug binding or ATP hydrolysis a¡ect
P-gp conformation?
3. Importance of the two nucleotide-binding domains
A fundamental question about P-gp was the role
of the nucleotide-binding domains (NBDs). Shima-
buku et al. [36] fused the NH2-terminal half or the
COOH-terminal half of P-gp with lacZ and showed
that only the NH2-terminal half could hydrolyze
ATP with a speci¢c activity of 180 nmol Pi/min/mg
enzyme. The COOH-terminal half-lacZ fusion was
not expressed in su⁄cient amounts in NIH 3T3 or
yeast cells for measuring activity. When we expressed
the NH2- and COOH-terminal halves as separate
polypeptides in Sf9 insect cells, however, both halves
had low levels of basal ATPase activity [28]. These
results suggested that both nucleotide-binding do-
mains could hydrolyze ATP. A similar conclusion
was reported for the hamster P-gp [37]. It was inter-
esting to note that substrate-stimulated ATPase ac-
tivity was only observed when both halves were co-
expressed. The absence of drug-stimulated ATPase
activity in each half-molecule suggested that the
ATPase activities were not coupled to drug/substrate
Fig. 4. Role of the nucleotide-binding domains. A cysteine residue was introduced into either Walker A consensus site (Cys431 or
Cys1074) of Cys-less P-gp. The ATPase activities of the mutants in the presence or absence of NEM (3 or +NEM) were determined.
The ATPase activity of Cys-less P-gp was not inhibited by NEM.
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binding. These results showed that coupling of ATP-
ase activity to drug binding requires interaction be-
tween both halves of P-gp. Al-Shawi et al. [38]
showed that the ATPase activity of hamster P-gp
was inhibited by N-ethylmaleimide (NEM). Maximal
inactivation of ATPase activity was coincident with
incorporation of two NEMs per P-gp. Labeling by
NEM occurred at two sites, with equal distribution
of label between the NH2 and COOH halves of the
molecule. Labeling by NEM was inhibited by the
presence of ATP. Therefore, it was predicted that
the cysteine residues in the Walker A consensus se-
quences of either NBD (GNSGCGKS and
GSSGCGKS, respectively) likely reacted with NEM.
To test the contribution of either NBD to P-gp
function, the Cys-less P-gp was modi¢ed so that a
single cysteine residue was introduced into the
Walker A consensus sequence (C431 or C1074) in
either NBD (Fig. 4). Covalent modi¢cation of either
C431 or C1074 with NEM inactivated the basal or
drug-stimulated ATPase activities [39]. In both mu-
tants, inactivation of ATPase activity was inhibited
by the presence of ATP. The NBDs did not appear
to be equivalent since the concentrations of NEM
required for inhibiting ATPase activity were di¡erent
(half-maximal inhibition of 7 WM for C431 and 35
WM for C1074). These results suggested that both
nucleotide-binding domains are essential for activity,
and that both NBDs must function in a regulated
manner. The Senior group have used vanadate trap-
ping of nucleotides to show that only one NBD is in
a catalytic transition state at a time, and have pro-
posed an alternating site catalysis mechanism [40].
4. Topology of P-gp
The Cys-less P-gp was a useful tool for determin-
ing the topology of P-gp at the cell surface. Single
cysteine residues were introduced at di¡erent loca-
tions in P-gp. Mutants that still conferred drug re-
sistance in transfected cells were used for topology
studies. Study of the inactive molecules may not be
informative because they may be misfolded. The mu-
tant P-gps were transiently expressed in HEK 293
cells and reacted with thiol-speci¢c membrane-per-
meant (biotin maleimide; 3-(N-maleimidylpropionyl)
biocytin; Molecular Probes, Inc.) or membrane-im-
permeant (stilbenedisulfonate maleimide; 4-acetami-
do-4P-maleimidylstilbene-2,2P-disulfonic acid) com-
pounds. The rationale was that treatment with
biotin maleimide would biotinylate any Cys residues,
and that pretreatment with membrane-impermeant
stilbenedisulfonate maleimide would block the ex-
posed extracellular cysteine residues. The biotinyl-
ated proteins were immunoprecipitated and detected
by Western blot analysis with streptavidin conju-
gated to horseradish peroxidase [23]. The topology
obtained was consistent with the model predicting six
TM segments in each homologous half of P-gp. Kast
et al. [41,42] inserted a small antigenic peptide epit-
ope (YPYDVPDYAIEGR) containing part of the
hemagglutinin (HA) of in£uenza virus at various po-
sitions in the mouse P-gp, and showed that the top-
ology was consistent with the predicted model (‘6+6’
TM model). The topology of P-gp (Fig. 2) is still
controversial. Other topologies (for example, six
TM segments in the NH2 half and four TM segments
in the COOH half; ‘6+4’ TM model) have also been
reported [43^47]. A possible explanation for these
alternative topologies is that they do exist at the
cell surface, but at such low levels that it may not
be possible to isolate enough material for biochem-
ical studies. Another explanation is that the di¡erent
topologies could be inherent to the folding properties
of the truncated forms of P-gp used in these studies.
Point mutations in P-gp can indeed alter the levels of
Fig. 5. Topologies of P-gp. Wild-type P-gp showing the pre-
dicted ‘6+6’ TM arrangement. Some mutations such as E875C
cause about 50% of P-gp to adopt a ‘6+4’ TM arrangement. In
this conformation, N809 in the loop connecting TMs 8 and 9 is
glycosylated.
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the di¡erent topologies present in the cell. For exam-
ple, the mutation E875C promotes the formation of
a topology where the predicted cytoplasmic loop 3 is
on the opposite side of the membrane and where
Q809 is now glycosylated (Fig. 5). It appears, how-
ever, that only P-gp with the ‘6+6’ TM arrangement
interacts with drug substrates [48].
Determining the topology of polytopic membranes
using cysteine-scanning mutagenesis and thiol-specif-
ic compounds has become increasingly popular. For
example, this approach has been successfully used for
the serotonin transporter [49], the F1F0 ATP syn-
thase [50,51], AE1 protein [52], the yeast vacuolar
proton ATPase [53] and the bradykinin L2 receptor
[54]. A variety of other thiol-reactive compounds
have also been used. For example, N-biotinylamino-
ethylmethane thiosulfonate (MTSEA-biotin) was
used to label the serotonin reporter [49].
5. Identi¢cation of residues in the drug-binding
domains
In order to understand how P-gp is able to trans-
port such a variety of hydrophobic compounds, it is
important to identify the residues that participate in
drug binding. One method for identifying the do-
mains that bind drugs is to use photoactive radio-
active analogs of drug substrates to label P-gp, fol-
lowed by proteolytic or chemical cleavage to identify
the labeled fragment. The results from such studies
suggest that the photolabeled residue(s) are in TM3
[55], TM4 [55,56], TM5 [55,57], TM6 [55,57,58],
TM7 [59], TM8 [59], TM11 [60] and TM12 [58^61].
Another approach has been to use mutational
analysis to identify residues that when changed, alter
activity or substrate speci¢city of the transporter
[25,30,31,62^65]. The results from such studies sug-
gest that residues on one face of TM segments 5, 6,
11 and 12 are particularly sensitive to mutations. A
potential problem, however, is that the mutations in
most domains, including the nucleotide-binding do-
mains [66,67] can alter the substrate speci¢city of P-
gp. It is also di⁄cult to determine whether mutations
a¡ecting substrate speci¢city are due to functional
perturbations or due to perturbations in the global
structure of P-gp. An example is the spontaneous
mutation G185V that conferred increased resistance
to colchicine and decreased resistance to vinblastine
[68,69]. This mutation was subsequently found to
have pleiotropic e¡ects on P-gp as a result of struc-
tural alterations [70].
A quite di¡erent method for identifying residues
that line the drug-binding sites would be to use cys-
teine-scanning mutagenesis with a thiol-reactive sub-
strate. Once a reactive residue is identi¢ed then pro-
tection experiments can be used to identify whether
that particular residue contributes to the binding of
other substrates.
Dibromobimane (dBBn) is a thiol-reactive com-
pound and a substrate of P-gp. It is a hydrophobic
compound (Fig. 6) containing two thiol-reactive
groups, and can also be used as a thiol crosslinking
reagent. It stimulates the ATPase activity of Cys-less
P-gp about 8-fold at a concentration of 1 mM [71].
Another useful property of dBBn is that it can be
converted to a non-substrate (i.e. does not stimulate
ATPase activity of P-gp) by quenching with cysteine.
Initial studies were done on residues in TM6 and
TM12. The ATPase activities of mutants L339C
and A342C (TM6), and mutants L975C, V982C
and A985C (TM12) were inhibited by dBBn. Protec-
tion from inactivation was observed with verapamil,
vinblastine and colchicine, suggesting that these res-
idues were important for interaction of these sub-
strates with P-gp. While this approach has many ad-
vantages, one drawback is that all residues that
participate in binding dBBn may not react with it.
6. Disul¢de crosslinking to assess TM packing in the
membrane
Most evidence suggests that the TM segments in-
teract with substrates. TM6 and TM12 appear to be
Fig. 6. Structure of dibromobimane. Dibromobimane is a thiol-
speci¢c compound that stimulated the ATPase activity of Cys-
less P-gp. It can be used as a crosslinking agent due to the
presence of a bifunctional group.
BBAMEM 77711 19-11-99
T.W. Loo, D.M. Clarke / Biochimica et Biophysica Acta 1461 (1999) 315^325 321
particularly important. In the linear model of P-gp,
TM6 and TM12 are relatively far apart. If TM6 and
TM12 contribute to the same drug-binding site, then
they would be expected to be close to each other in
the three-dimensional structure of the protein. Such
high-resolution structures have not been available
due to technical di⁄culties in crystallizing P-gp for
X-ray di¡raction studies. A relatively low resolution
structure of P-gp (25 Aî ), however, was recently re-
ported by Rosenberg et al. [72].
A method that does not require large amounts of
protein for studying the TM packing of P-gp in the
membrane is disul¢de crosslinking analysis. Such an
approach was initially used to characterize the oligo-
meric nature of the aspartate and Tar receptors in
bacteria [73^76]. These investigators took advantage
of the fact that these proteins formed stable homo-
dimers and that the crosslinked products were readily
detected by shifts in their electrophoretic mobilities
in SDS-PAGE gels.
Changes in the electrophoretic mobility of P-gp in
SDS-PAGE gels were used to assay for disul¢de
crosslinking between residues in TM6 and TM12.
Crosslinking was detected in mutants F343C/
M986C, G346C/G989C and P350/S993C [77,78].
Crosslinking experiments with the half molecules of
P-gp con¢rmed that the changes in electrophoretic
mobilities of these mutants were indeed due to disul-
¢de crosslinking [77]. The NH2 and COOH halves of
P-gp interact because they show drug-stimulated
ATPase activity when coexpressed in the same cell.
Cysteine residues were introduced into the Cys-less
forms of either half-molecule. They were coexpressed
and assayed for the presence of crosslinked products.
The results showed that F343C (TM6)+M986C
(TM12), G346C (TM6)+G989C (TM12), and
P350C (TM6)+S993C (TM12) (Loo and Clarke, un-
published observations) could be crosslinked. These
results suggest that TM6 and TM12 close together in
the three-dimensional structure of P-gp.
A considerable amount of crosslinking data will be
required for understanding the packing of TM seg-
ments in the membrane. To this end, development of
a feasible working model might provide a clearer
picture for designing future crosslinking experiments.
Data from the TM6/TM12 crosslinking experiments
Fig. 8. Model of conformational changes between TM6 and TM12 during drug transport. (A) In the absence of drug substrates or
ATP, crosslinking is observed between Cys residues in TM6 and TM12 that are close to the cytoplasmic side of the lipid bilayer. (B)
Binding of drug substrate prevents crosslinking between TM6 and TM12. (C) ATP hydrolysis causes movement between TM6 and
TM12 such that crosslinking is also detected between residues that are close to the extracellular side of the bilayer.
Fig. 7. Models of TM packing in the membrane. Disul¢de
crosslinking studies show that TMs 6 and 12 are close together.
On this basis, aerial views of two models are presented. (A)
The ‘Parallel’ model in which TMs 1^7 are parallel to TMs 7^
12. (B) The ‘Cyclone’ model in which TMs 1^6 are anti-parallel
to TMs 7^12. The TMs are represented as numbered circles.
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can be used to design two practical models. In the
‘Parallel’ model, TMs 1^6 are parallel to TMs 7^12
(Fig. 7A). The model predicts that crosslinking
would be possible between TM1/TM7, TM2/TM8,
TM3/TM9 and so on. Another arrangement of the
TMs is the ‘Cyclone’ model (Fig. 7B). In this model,
TMs 1^6 are anti-parallel to TMs 7^12. This model
predicts a di¡erent pattern of crosslinking, with
crosslinking expected between TMs 4^6 and TMs
10^12, and not between TMs 1 and 2 and TMs 7
and 8. More recent results support the ‘Cyclone’
model (Loo and Clarke, manuscript in preparation).
Crosslinking studies are quite informative, since
they can provide insight into the dynamic nature of
the TM segments. The presence of substrates and
ATP during crosslinking changes the pattern of
crosslinking and can be used to detect the range of
movement of the TM segments. These results provide
insight into the conformation changes that occur
during the catalytic cycle of P-gp. An example is
the change in the pattern of crosslinking between
TM6 and TM12 in the presence of substrates or
ATP. The crosslinking pattern seen in mutants
F343C/M986C, G346C/G989C and P350C/S993C
was inhibited by the presence of substrates such as
verapamil, vinblastine, cyclosporin A or colchicine
[78]. It seemed that the presence of substrates in-
creased the distance between these crosslinkable res-
idues. An alternative explanation is that the sub-
strates occupy the space between the cysteines. The
presence of ATP had a di¡erent e¡ect on crosslink-
ing between TMs 6 and 12. Mutant L332C (TM6)/
L975C (TM12) is normally not crosslinkable except
in the presence of ATP. Hydrolysis of ATP is re-
quired since the presence of ATP+vanadate, a non-
hydrolyzable ATP analog (AMP.PNP), or ADP did
not induce crosslinking [78]. Data from these types of
experiment can be incorporated into a model as
shown in Fig. 8. In the absence of drug substrates,
the residues lining one face of TM6 are close to one
face of TM12. Binding of drug substrates by P-gp
leads to an increase in the distance between TM6
and TM12. Hydrolysis of ATP induces conforma-
tional changes that result in movement between
TM6 and TM12 and subsequent drug e¥ux. If
TM6 and TM12 are locked in a ¢xed position by
crosslinking before addition of drug substrate and
ATP, then drug-stimulated ATPase activity is not
detected [78]. In summary, cysteine-scanning muta-
genesis combined with thiol-modi¢cation chemistry
has contributed much to our understanding of the
structure and mechanism of P-gp.
Future studies will answer questions such as: (1)
Do all substrates bind to the same region of P-gp?
(2) Which model best explains how the TM segments
are packed in the membrane? (3) Do other TM seg-
ments show conformation changes upon binding of
substrate or during ATP hydrolysis? (4) Why do
some mutations inhibit biosynthesis? (5) How do
substrates correct processing defects?
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